Plant lectins as prospective antiviral biomolecules in the search for COVID-19 eradication strategies.

Lectins or clusters of carbohydrate-binding proteins of non-immune origin are distributed chiefly in the Plantae. Lectins have potent anti-infectivity properties for several RNA viruses including SARS-CoV-2. The primary purpose of this review is to review the ability of lectins mediated potential biotherapeutic and bioprophylactic strategy against coronavirus causing COVID-19. Lectins have binding affinity to the glycans of SARS-COV-2 Spike glycoprotein that has N-glycosylation sites. Apart from this, the complement lectin pathway is a "first line host defense" against the viral infection that is activated by mannose-binding lectins. Mannose-binding lectins deficiency in serum influences innate immunity of the host and facilitates infectious diseases including COVID-19. Our accumulated evidence obtained from scientific databases particularly PubMed and Google Scholar databases indicate that mannose-specific/mannose-binding lectins (MBL) have potent efficacies like anti-infectivity, complement cascade induction, immunoadjuvants, DC-SIGN antagonists, or glycomimetic approach, which can prove useful in the strategy of COVID-19 combat along with the glycobiological aspects of SARS-CoV-2 infections and antiviral immunity. For example, plant-derived mannose-specific lectins BanLac, FRIL, Lentil, and GRFT from red algae can inhibit and neutralize SARS-CoV-2 infectivity, as confirmed with in-vitro, in-vivo, and in-silico assessments. Furthermore, Bangladesh has a noteworthy resource of antiviral medicinal plants as well as plant lectins. Intensifying research on the antiviral plant lectins, adopting a glyco-biotechnological approach, and with deeper insights into the "glycovirological" aspects may result in the designing of alternative and potent blueprints against the 21st century's biological pandemic of SARS-CoV-2 causing COVID-19.

[Strategy for the South-South cooperation on schistosomiasis control under the Belt and Road Initiative].

Following the concerted efforts for nearly 70 years, great successes have been achieved in the national schistosomiasis control programme in China. Currently, the national schistosomiasis control programme in China is facing the challenges to solve the problems during the"final mile"stage towards schistosomiasis elimination, and contribute Chinese experiences, Chinese strategy and Chinese wisdom to the global schistosomiasis control programmes, so as to facilitate the transformation of the joint efforts in the Belt and Road Initiative to a high-quality development, thereby well supporting the activities on global health security. This paper analyzes the current global status of schistosomiasis and the challenges of the global schistosomiasis control programmes, describes the basis for the cooperation on schistosomiasis control among the countries along the Belt and Road Initiative, illustrates the challenges for translation of Chinese experiences and techniques in schistosomiasis control to other diseaseendemic countries, and proposes the patterns and prospects of the South-South cooperation on schistosomiasis control under the Belt and Road Initiative.

Threats to the Effectiveness of Malaria Treatment.

In reaction to the speed and ease with which a high level of resistance against P. falciparum was induced in vivo in a mouse NOD/SCID IL-Ry-/- model by sub-therapeutic doses of artesunate [2], this text begins a plea for concrete measures to limit the risk of eventually appearing the same phenomenon in the field, including a strengthening of the fight against the use of artesunate oral monotherapy, tablet often under-dosed or artemisinin herbal tea and the adoption of more reliable and more efficient means than those currently used to detect the emergence of resistance earlier and a relaunch of the search for new antimalarials.

World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat.

Helicobacter pylori-associated gastritis leads to the development of gastric cancer. Kyoto global consensus report on H. pylori gastritis recommended H. pylori eradication therapy to prevent gastric cancer. To manage H. pylori infection, it is important to choose the appropriate regimen considering regional differences in resistance to clarithromycin and metronidazole. Quinolones and rifabutin-containing regimens are useful as third- and fourth-line rescue therapies.

Perspectiva histórica de antimaláricos de origen natural / Historical perspective of antimalarials of natural origin

Hoy, muchas enfermedades son tratadas gracias al descubrimiento de compuestos a partir de las plantas, lo que evidencia que estas juegan un papel significativo en el descubrimiento y desarrollo de nuevos fármacos. Una de las alternativas para el control de la morbi-mortalidad por malaria es la quimioterapia, la cual ha sido posible gracias al descubrimiento de compuestos a partir de las plantas. En la actualidad, cerca de la mitad de los fármacos antimaláricos disponibles son compuestos naturales o están relacionados con ellos. En esta revisión se hace un recuento histórico del origen y desarrollo de los principales antimaláricos como instrumento de hechos arquitectónicos, que mantienen una estrecha relación con los referentes antimaláricos, que sirven de modelos para profundizar en la búsqueda de nuevas sustancias químicas naturales que podrían contribuir al control de una devastadora enfermedad como la malaria, donde se están presentando cepas resistentes de Plasmodium a los principales tratamientos, falla terapéutica, además de un escaso acceso a los medicamentos, entre otros factores; que complican su prevención y tratamiento (AU)

Today, many diseases are treated thanks to the discovery of compounds from plants, which shows that they play a significant role in the discovery and development of new drugs. One of the alternatives for the control of malaria morbidity and mortality is chemotherapy, which has been made possible by the discovery of compounds from plants. At present, about half of the available antimalarials drugs are naturally occurring compounds or are related to them. This review provides a historical account of the origin and development of the main antimalarials as an instrument of architectural facts, which maintains a close relationship with the antimalarials referents, which serve as models to deepen the search for new natural chemical substances that could contribute to the Control of a devastating disease like malaria, where resistant strains of Plasmodium are being presented to the main treatments, therapeutic failure, in addition to poor access to medicines, among other factors; which complicate their prevention and treatment (AU)

Discovering New Transmission-Blocking Antimalarial Compounds: Challenges and Opportunities.

The ability to target human-mosquito parasite transmission challenges global malaria elimination. However, it is not obvious what a transmission-blocking drug will look like; should it target only parasite transmission stages; be combined with a partner drug killing the pathogenic asexual stages; or kill both the sexual and asexual blood stages, preferably displaying polypharmacology? The development of transmission-blocking antimalarials requires objective analyses of the current strategies. Here, pertinent issues and questions regarding the target candidate profile of a transmission-blocking compound, and its role in malaria elimination strategies, are highlighted and novel perspectives proposed. The essential role of a test cascade that integrates screening and validation strategies to identify next-generation transmission-blocking antimalarials is emphasised.

Operational issues and barriers to implementation of prevention of mother-to-child transmission of HIV (PMTCT) interventions in Sub-Saharan Africa.

Over the past 10 years substantial progress has been made in the implementation of prevention of mother-to-child transmission of HIV (PMTCT) interventions in Sub-Saharan Africa (SSA). In spite of this, new pediatric infections remain unacceptably high, contributing the majority (>90%) of the estimated 390,000 infections globally in 2010; and yet prolonged breastfeeding remains the norm and crucial to overall infant survival. However, there is reason for optimism given the 2010 World Health Organization PMTCT recommendations: to start HIV infected pregnant women with CD4 cell counts less than 350 cells/mm(3) on lifelong antiretroviral therapy (ART); and for mothers not eligible for ART to provide efficacious maternal and/or infant PMTCT antiretroviral (ARV) regimens to be taken during pregnancy, labor/delivery and through breastfeeding. Current attention is on whether to extend maternal ARVs for life once triple ARV PMTCT regimens are started. To dramatically reduce new pediatric infections, individual countries need to politically commit to rapid scale-up of a multi-pronged PMTCT effort: including primary prevention to reduce HIV incidence among women of reproductive age; increased access to family planning services; HIV screening of all pregnant and breastfeeding women followed by ART or ARVs for PMTCT; and comprehensive care for HIV affected families. Efforts to achieve population-level success in SSA need to critically address operational issues and challenges to implementation (health system) and utilization (social, economic and cultural barriers), at the country, health centre and client level that have led to the relatively slow progress in the scale-up of PMTCT strategies.

Progress, challenges, and new opportunities for the prevention of mother-to-child transmission of HIV under the US President's Emergency Plan for AIDS Relief.

In June 2011, the Joint United Nations Programme on HIV/AIDS, the US President's Emergency Plan for AIDS Relief (PEPFAR), and other collaborators outlined a transformative plan to virtually eliminate pediatric AIDS worldwide. The ambitious targets of this initiative included a 90% reduction in new pediatric HIV infections and a 50% reduction in HIV-related maternal mortality--all by 2015. PEPFAR has made an unprecedented commitment to the expansion and improvement of prevention of mother-to-child HIV transmission (PMTCT) services globally and is expected to play a critical role in reaching the virtual elimination target. To date, PEPFAR has been instrumental in the success of many national programs, including expanded coverage of PMTCT services, an enhanced continuum of care between PMTCT and HIV care and treatment, provision of more efficacious regimens for antiretroviral prophylaxis, design of innovative but simplified PMTCT approaches, and development of new strategies to evaluate program effectiveness. These accomplishments have been made through collaborative efforts with host governments, United Nations agencies, other donors (eg, the Global Fund for AIDS, Tuberculosis, and Malaria), nongovernmental organizations, and private sector partners. To successfully meet the ambitious global targets to prevent new infant HIV infections, PEPFAR must continue to leverage the existing PMTCT platform, while developing innovative approaches to rapidly expand quality HIV services. PEPFAR must also carefully integrate PMTCT into the broader combination prevention agenda for HIV, so that real progress can be made toward an "AIDS-free generation" worldwide.